Investor Watch | Biotech Hedge Fund Losses Mount but Enormous Sums of Capital Available

Join The Conversation! | https://trialsitenews.com/
While many people just assume biotech investors make big returns during the pandemic, perhaps nothing could be farther from the truth for many investors in this traditionally high volatile market. Recently, the Wall Street Journal reported that “The performance of the biotech sector this year is worse than all 11 of the S&P 500’s sectors.” Biotech stock prices overall have fallen after 2019 and 2020 surges. While some biotech and pharma companies were “winners,” most have missed out on the opportunity to monetize the pandemic. Looming questions and issues mount—spooking potential investors—which, of course, can adversely impact share prices. Do some noticeable losses in hedge funds introduce more risk or opportunity?